Article

Larger graft available for damaged ocular surfaces

A new, larger designed size of AmnioGraft biologic ocular transplantation graft, AmnioGraft AG-5050 (Bio-Tissue Inc.), is now available for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. The graft consists of amniotic membrane to protect, repair, and heal damaged eye surfaces.

 

Miami-A new, larger designed size of AmnioGraft biologic ocular transplantation graft, AmnioGraft AG-5050 (Bio-Tissue Inc.), is now available for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. The graft consists of amniotic membrane to protect, repair, and heal damaged eye surfaces.

At 5.0 by 5.0 cm, the new graft provides greater coverage to help heal the ocular surface inflammation and ulceration found in Stevens-Johnson syndrome/toxic epidermal necrolysis. It provides the amniotic membrane’s unique wound repair and healing actions to reduce inflammation and formation of abnormal blood vessels, prevent scarring, and minimize pain.

“When patients are treated early, cryopreserved amniotic membrane works very well in the acute treatment of the eye for these diseases as it has therapeutic qualities that help the eye surface heal faster,” said Scheffer C.G. Tseng, MD, PhD. “Cryopreserved amniotic membrane has changed how we treat patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and is helping to save sight.”

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.